FDA

Interactive Visualization of Standardized CDISC-SEND-Formatted Toxicology Study Data Using R Shiny

The standardization of nonclinical study data by the Clinical Data Interchange Standards Consortium (CDISC) via the Standard for Exchange of Nonclinical Data (SEND) has created an opportunity for the collaborative development and use of open source …

The use of R for improved reproducibility of biomarker detection in liquid biopsies

Research reproducibility has been heatedly discussed in recent years. Some authors have pointed out that a large portion of published research findings is incorrect and/or irreproducible. Some state that the medical literature is as reliable as …

Using R for Generic Drug Evaluation and SABE R-package for Assessing Bioequivalence of Topical Dermatological Products

Determination of bioequivalence (BE), a crucial part of the evaluation of generic drugs, may depend on clinical endpoint studies, pharmacokinetic (PK) studies of bioavailability, and In-Vitro tests, among others. Additionally, in reviewing …

Unification in a Compartmentalized Culture

When it comes to analytics of data collected in medical research, today’s culture is compartmentalized – not only across institutions, but even within institutions. Such a culture stagnates analytical development and limits the ability to fully …

Modernizing the new drug regulatory program in FDA/CDER: Can Collaborations and Sharing Help?

Lilliam will be presenting a perspective on what the office of computational science is doing to support regulatory review for safety assessments. She will explore the concept of collaborations and sharing to support process and transparency, along …

Using R in a regulatory environment: some FDA perspectives

The United States Food and Drug Administration (FDA) uses a variety of statistical software packages for review and research. This presentation will focus on the uses of R in the Center for Drug Evaluation and Research (CDER), including graphics for …